AKT1 and pulmonary fibrosis: In 2019, the Food and Drug Administration (FDA) approved alpelisib,a potent selective ATP-competitive inhibitor of PI3Kα, for treatingpatients with severe PIK3CA-related overgrowth spectrum (PROS), i.e.,a group of diverse overgrowth disorders caused by PIK3CA mutations. Additionally, several compounds were analyzedfocusing on the PI3K/AKT pathway for idiopathic pulmonary fibrosis(IPF), and post-CoViD-19 pulmonary fibrosis (PC19-PFor PCPF),−,  due to similaritiesbetween IPF and PCPF.,